ClinicalTrials.gg
CompletedNCT07641881Updated Aug 13, 2026

A Bioequivalence Study Between Two Casdatifan Tablet Strengths and Food Effect Study of Casdatifan in Healthy Adult Participants

A Phase 1 interventional study of Casdatifan in Healthy Participants, sponsored by Arcus Biosciences, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Arcus Biosciences, Inc. · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to compare the single-dose pharmacokinetics (PK) of casdatifan 100 mg versus four 25 mg tablets under fasting conditions in healthy adult participants, and to evaluate the effect of food on the single-dose PK of casdatifan 100 mg administered as four 25 mg tablets in healthy adult participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • Casdatifan
  • AB521
  • HIF-2α
  • Pharmacokinetics
03

In context

Lead sponsor

Arcus Biosciences, Inc. is the lead sponsor of 32 studies on the registry; 4 are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting.
  • ≥ 18.0 and ≤ 32.0 kg/m2 and body weight ≥ 45 kg at the screening visit.
  • Medically healthy with no medical history, physical examination, clinical laboratory profiles, standard vital signs, and ECGs, as deemed by the PI or designee.
  • Able to swallow multiple tablets.
  • Has adequate peripheral venous access.

Exclusion criteria

Exclusion Criteria:

  • Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
  • History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
  • History of asthma or (including childhood), food allergies or anaphylaxis, as deemed by PI or designee.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of asymptomatic gallstones).
  • Seizure (excluding simple febrile seizure), epilepsy, severe head injury, multiple sclerosis, or other known neurological conditions which the PI or designee considers to be clinically significant.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Treatment A

    Participants will receive 4 X 25 mg tablets of casdatifan.

    Drug: Casdatifan

  • Experimental
    Treatment B

    Participants will receive 1 X 100 mg tablets of casdatifan.

    Drug: Casdatifan

  • Experimental
    Treatment C

    Participants will receive 4 X 25 mg tablets of casdatifan under fed conditions.

    Drug: Casdatifan

Interventions

  • Administered as specified in the treatment arm

    Also known as: AB521

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration for casdatifan

    Time frame: Up to 168 hours post each dose

  2. Area under the concentration-time curve for casdatifan

    Time frame: Up to 168 hours post each dose

Secondary outcomes

  1. Time to reach Cmax (Tmax) for casdatifan

    Time frame: Up to 168 hours post each dose

  2. Lag time (Tlag) for casdatifan

    Time frame: Up to 168 hours post each dose

  3. Apparent first-order terminal elimination rate constant (Kel) for casdatifan

    Time frame: Up to 168 hours post each dose

  4. Percent of AUC0-inf extrapolated for casdatifan

    Time frame: Up to 168 hours post each dose

  5. Apparent first-order terminal elimination half-life (t½) for casdatifan

    Time frame: Up to 168 hours post each dose

  6. Apparent total clearance after extravascular (oral) administration (CL/F) for casdatifan

    Time frame: Up to 168 hours post each dose

  7. Apparent total clearance after extravascular (oral) administration (Vz/F) for casdatifan

    Time frame: Up to 168 hours post each dose

  8. Number of participants experiencing Adverse Events (AEs)

    Time frame: Up to 43 days

07

Study locations

1 site
  • Research Site
    Tempe, Arizona 85283, United States
08

References and documents

Individual participant data

Plan to share: Yes — Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. For more information, please visit our website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Data sharing details ↗ · trials.arcusbio.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Jul 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 11, 2026
StartActual
May 29, 2026
Primary completionActual
Jul 3, 2026
CompletionActual
Aug 7, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07641881
Responsible party
Sponsor
First posted
Jun 11, 2026
Start date
May 29, 2026
Primary completion
Jul 3, 2026
Completion
Aug 7, 2026
Last update
Aug 13, 2026

Study contacts

Medical Director
study director · Arcus Biosciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Casdatifan

Start the discussion